Riluzole Oral Suspension · 959 days since initial FDA posting
Brand: TIGLUTIK
FDA lists Riluzole Oral Suspension as Active Shortage (EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)).
Availability on file: Unavailable
Riluzole Oral Suspension: Active Shortage
Unavailable Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Riluzole Oral Suspension
- Manufacturer
- EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
- Dosage Form
- Oral Suspension
- Presentation
- Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)
- Package NDC
- 70726-0303-2
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Jan 26, 2024
- Last Updated
- Mar 16, 2026
- Therapeutic Category
- Neurology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing
Nearby, Other Riluzole Shortage Records
Riluzole Oral Suspension
EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
Oral Suspension
Riluzole Oral Suspension
EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
Oral Suspension
Riluzole Oral Suspension
EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
Oral Suspension
FDA reason on file: Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing. General shortage guidance lives on the tracker hub.